新型口服生物可利用的流感PB2β-氨基酸氮杂吲哚抑制剂的发现。
Discovery of Novel, Orally Bioavailable β-Amino Acid Azaindole Inhibitors of Influenza PB2.
作者信息
Farmer Luc J, Clark Michael P, Boyd Michael J, Perola Emanuele, Jones Steven M, Tsai Alice, Jacobs Marc D, Bandarage Upul K, Ledeboer Mark W, Wang Tiansheng, Deng Hongbo, Ledford Brian, Gu Wenxin, Duffy John P, Bethiel Randy S, Shannon Dean, Byrn Randal A, Leeman Joshua R, Rijnbrand Rene, Bennett Hamilton B, O'Brien Colleen, Memmott Christine, Nti-Addae Kwame, Bennani Youssef L, Charifson Paul S
机构信息
Vertex Pharmaceuticals Inc. , 50 Northern Avenue, Boston, Massachusetts 02210, United States.
出版信息
ACS Med Chem Lett. 2017 Jan 20;8(2):256-260. doi: 10.1021/acsmedchemlett.6b00486. eCollection 2017 Feb 9.
Abstract
In our efforts to develop novel small-molecule inhibitors for the treatment of influenza, we utilized molecular modeling and the X-ray crystal structure of the PB2 subunit of the influenza polymerase to optimize a series of acyclic β-amino acid inhibitors, highlighted by compound . Compound showed good oral exposure in both rat and mouse. More importantly, it showed strong potency versus multiple influenza-A strains, including pandemic 2009 H1N1 and avian H5N1 strains and showed a strong efficacy profile in a mouse influenza model even when treatment was initiated 48 h after infection. Compound offers good oral bioavailability with great potential for the treatment of both pandemic and seasonal influenza.
摘要
在我们开发用于治疗流感的新型小分子抑制剂的过程中，我们利用分子建模和流感病毒聚合酶PB2亚基的X射线晶体结构来优化一系列无环β-氨基酸抑制剂，化合物 尤为突出。化合物 在大鼠和小鼠体内均表现出良好的口服暴露性。更重要的是，它对多种甲型流感病毒株具有强大的效力，包括2009年大流行的H1N1和禽流感H5N1毒株，并且在小鼠流感模型中显示出强大的疗效，即使在感染后48小时开始治疗也是如此。化合物 具有良好的口服生物利用度，在治疗大流行和季节性流感方面具有巨大潜力。
相似文献
1
Discovery of Novel, Orally Bioavailable β-Amino Acid Azaindole Inhibitors of Influenza PB2.新型口服生物可利用的流感PB2β-氨基酸氮杂吲哚抑制剂的发现。
ACS Med Chem Lett. 2017 Jan 20;8(2):256-260. doi: 10.1021/acsmedchemlett.6b00486. eCollection 2017 Feb 9.
2
Discovery of a novel, first-in-class, orally bioavailable azaindole inhibitor (VX-787) of influenza PB2.发现一种新型、首创的、可口服的含氮吲哚抑制剂（VX-787），可抑制流感 PB2。
J Med Chem. 2014 Aug 14;57(15):6668-78. doi: 10.1021/jm5007275. Epub 2014 Jul 24.
3
Novel 2-Substituted 7-Azaindole and 7-Azaindazole Analogues as Potential Antiviral Agents for the Treatment of Influenza.新型2-取代7-氮杂吲哚和7-氮杂吲唑类似物作为治疗流感的潜在抗病毒药物
ACS Med Chem Lett. 2017 Jan 18;8(2):261-265. doi: 10.1021/acsmedchemlett.6b00487. eCollection 2017 Feb 9.
4
Reassortant H5N1 Avian Influenza Virus Bearing PB2 Gene From a 2009 Pandemic H1N1 Exhibits Increased Pathogenicity in Mice.携带2009年大流行H1N1的PB2基因的重配H5N1禽流感病毒在小鼠中致病性增强。
Front Microbiol. 2018 Apr 3;9:631. doi: 10.3389/fmicb.2018.00631. eCollection 2018.
5
Multiple Natural Substitutions in Avian Influenza A Virus PB2 Facilitate Efficient Replication in Human Cells.甲型禽流感病毒PB2中的多个自然替换促进其在人类细胞中的高效复制。
J Virol. 2016 Jun 10;90(13):5928-5938. doi: 10.1128/JVI.00130-16. Print 2016 Jul 1.
6
Preclinical activity of VX-787, a first-in-class, orally bioavailable inhibitor of the influenza virus polymerase PB2 subunit.VX-787的临床前活性，一种一流的、口服生物可利用的流感病毒聚合酶PB2亚基抑制剂。
Antimicrob Agents Chemother. 2015 Mar;59(3):1569-82. doi: 10.1128/AAC.04623-14. Epub 2014 Dec 29.
7
Synthesis and structure-activity optimization of 7-azaindoles containing aza-β-amino acids targeting the influenza PB2 subunit.含氮杂-β-氨基酸的 7-氮茚并化合物的合成及针对流感 PB2 亚基的结构活性优化。
Eur J Med Chem. 2023 Mar 15;250:115185. doi: 10.1016/j.ejmech.2023.115185. Epub 2023 Feb 6.
8
A Small-Molecule Compound Has Anti-influenza A Virus Activity by Acting as a ''PB2 Inhibitor".小分子化合物通过充当“PB2 抑制剂”发挥抗甲型流感病毒活性。
Mol Pharm. 2018 Sep 4;15(9):4110-4120. doi: 10.1021/acs.molpharmaceut.8b00531. Epub 2018 Aug 23.
9
10
Isosteric replacements of the carboxylic acid of drug candidate VX-787: Effect of charge on antiviral potency and kinase activity of azaindole-based influenza PB2 inhibitors.候选药物VX-787羧酸的等排体替代：电荷对基于氮杂吲哚的流感PB2抑制剂抗病毒效力和激酶活性的影响。
Bioorg Med Chem Lett. 2015 May 1;25(9):1990-4. doi: 10.1016/j.bmcl.2015.03.013. Epub 2015 Mar 14.
引用本文的文献
1
Applications of Bridgehead Heterocycles in Drug Design and Medicinal Chemistry.桥头杂环在药物设计和药物化学中的应用。
Top Curr Chem (Cham). 2025 Mar 21;383(2):16. doi: 10.1007/s41061-025-00502-2.
2
Antiviral strategies against influenza virus: an update on approved and innovative therapeutic approaches.抗流感病毒的策略：已批准和创新治疗方法的最新进展
Cell Mol Life Sci. 2025 Feb 13;82(1):75. doi: 10.1007/s00018-025-05611-1.
3
Limited high-throughput screening compatibility of the phenuivirus cap-binding domain.酚病毒帽结合域的高通量筛选兼容性有限。
Sci Rep. 2023 Dec 20;13(1):22820. doi: 10.1038/s41598-023-50158-5.
4
Synthesis of Blue Emissive Quaternary 9,9-Disubstituted -Methyl-7-azaindole-Appended (Phenylethynyl)-fluorene Derivatives.蓝色发光季铵化9,9-二取代-甲基-7-氮杂吲哚连接的（苯乙炔基）芴衍生物的合成
ACS Omega. 2023 May 4;8(19):17043-17052. doi: 10.1021/acsomega.3c01255. eCollection 2023 May 16.
5
Cyclobutanes in Small-Molecule Drug Candidates.小分子候选药物中的环丁烷。
ChemMedChem. 2022 May 4;17(9):e202200020. doi: 10.1002/cmdc.202200020. Epub 2022 Mar 29.
6
Azaindole therapeutic agents.氮杂吲哚治疗剂。
Bioorg Med Chem. 2020 Dec 15;28(24):115830. doi: 10.1016/j.bmc.2020.115830. Epub 2020 Oct 30.
7
Investigation of Binding Affinity between Potential Antiviral Agents and PB2 Protein of Influenza A: Non-equilibrium Molecular Dynamics Simulation Approach.新型抗流感病毒药物与流感 A 病毒 PB2 蛋白结合亲和力的研究：非平衡分子动力学模拟方法。
Int J Med Sci. 2020 Jul 25;17(13):2031-2039. doi: 10.7150/ijms.46231. eCollection 2020.
8
Novel influenza polymerase PB2 inhibitors for the treatment of influenza A infection.新型流感聚合酶 PB2 抑制剂治疗甲型流感感染。
Bioorg Med Chem Lett. 2019 Oct 15;29(20):126639. doi: 10.1016/j.bmcl.2019.126639. Epub 2019 Aug 24.
9
Focusing on the Influenza Virus Polymerase Complex: Recent Progress in Drug Discovery and Assay Development.聚焦流感病毒聚合酶复合物：药物发现和检测方法开发的最新进展。
Curr Med Chem. 2019;26(13):2243-2263. doi: 10.2174/0929867325666180706112940.
10
Capped RNA primer binding to influenza polymerase and implications for the mechanism of cap-binding inhibitors.帽状 RNA 引物与流感聚合酶的结合及其对帽结合抑制剂机制的影响。
Nucleic Acids Res. 2018 Jan 25;46(2):956-971. doi: 10.1093/nar/gkx1210.
本文引用的文献
1
Novel Ranking System for Identifying Efficacious Anti-Influenza Virus PB2 Inhibitors.用于鉴定有效的抗流感病毒PB2抑制剂的新型排名系统
Antimicrob Agents Chemother. 2015 Oct;59(10):6007-16. doi: 10.1128/AAC.00781-15. Epub 2015 Jul 13.
2
Preclinical activity of VX-787, a first-in-class, orally bioavailable inhibitor of the influenza virus polymerase PB2 subunit.VX-787的临床前活性，一种一流的、口服生物可利用的流感病毒聚合酶PB2亚基抑制剂。
Antimicrob Agents Chemother. 2015 Mar;59(3):1569-82. doi: 10.1128/AAC.04623-14. Epub 2014 Dec 29.
3
Influenza viruses resistant to neuraminidase inhibitors.对神经氨酸酶抑制剂耐药的流感病毒。
Acta Biochim Pol. 2014;61(3):505-8. Epub 2014 Sep 8.
4
Discovery of a novel, first-in-class, orally bioavailable azaindole inhibitor (VX-787) of influenza PB2.发现一种新型、首创的、可口服的含氮吲哚抑制剂（VX-787），可抑制流感 PB2。
J Med Chem. 2014 Aug 14;57(15):6668-78. doi: 10.1021/jm5007275. Epub 2014 Jul 24.
5
New 7-methylguanine derivatives targeting the influenza polymerase PB2 cap-binding domain.针对流感聚合酶 PB2 帽结合域的新型 7-甲基鸟嘌呤衍生物。
J Med Chem. 2013 Nov 14;56(21):8915-30. doi: 10.1021/jm401369y. Epub 2013 Nov 6.
6
Airborne transmission of influenza A/H5N1 virus between ferrets.雪貂之间甲型流感病毒 H5N1 的空气传播。
Science. 2012 Jun 22;336(6088):1534-41. doi: 10.1126/science.1213362.
7
Avian influenza. Surprising twist in debate over lab-made H5N1.禽流感。实验室制造的H5N1病毒引发的辩论出现惊人转折。
Science. 2012 Mar 9;335(6073):1155-6. doi: 10.1126/science.335.6073.1155.
8
Estimates of deaths associated with seasonal influenza --- United States, 1976-2007.季节性流感相关死亡人数的估计——美国，1976-2007 年。
MMWR Morb Mortal Wkly Rep. 2010 Aug 27;59(33):1057-62.
9
The structural basis for cap binding by influenza virus polymerase subunit PB2.流感病毒聚合酶亚基PB2与帽结合的结构基础。
Nat Struct Mol Biol. 2008 May;15(5):500-6. doi: 10.1038/nsmb.1421. Epub 2008 May 4.
10
Neuraminidase inhibitors for influenza.用于治疗流感的神经氨酸酶抑制剂。
N Engl J Med. 2005 Sep 29;353(13):1363-73. doi: 10.1056/NEJMra050740.
Zotero 插件